POLO: Subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer

被引：1

作者：

Golan, T. ^{[1
]}

Hammel, P. ^{[2
]}

Reni, M. ^{[3
]}

Van Cutsem, E. ^{[4
]}

Mercade, T. Macarulla ^{[5
]}

Hall, M. J. ^{[6
]}

Park, J. O. ^{[7
]}

Hochhauser, D. ^{[8
]}

Arnold, D. ^{[9
]}

Oh, D-Y. ^{[10
]}

Reinacher-Schick, A. ^{[11
]}

Tortora, G. ^{[12
]}

Algul, H. ^{[13
]}

O'Reilly, E. M. ^{[14
]}

Bordia, S. ^{[15
]}

McGuinness, D. ^{[16
]}

Cui, K. Y. ^{[17
]}

Locker, G. ^{[18
]}

Kindler, H. ^{[19
]}

机构：

[1] Inst Oncol, Sheba Med Ctr, Oncol, Ramat Gan, Israel

[2] Hop Paul Brousse Assistance Publiquee Hopitaux Pa, Oncol, Villejuif, France

[3] Ist Sci San Raffaele, Med Oncol, IRCCS Osped, Milan, Italy

[4] Univ Hosp Gasthuisberg & KU Leuven, Digest Oncol, Leuven, Belgium

[5] Vall dHebron Univ Hosp, Med Oncol, Vall dHebron Inst Oncol, Barcelona, Spain

[6] Fox Chase Canc Ctr, Clin Genet, Philadelphia, PA USA

[7] Sungkyunkwan Univ, Samsung Med Ctr, Med Samsung Med Ctr, Sch Med, Seoul, South Korea

[8] UCL Canc Inst, Oncol, Paul OGorman Bldg, London, England

[9] Asklepios Tumorzentrum Hamburg AK Altona, Oncol Haematol, Palliat Care, Hamburg, Germany

[10] Seoul Natl Univ Hosp, Canc Res Inst, Med, Seoul, South Korea

[11] Ruhr Univ Bochum, Hematol, Oncol & Palliat Care, St Josef Hosp, Bochum, Germany

[12] Fondazione Policlin Gemelli IRCCS, Med Oncol, Rome, Italy

[13] Comprehens Canc Ctr Munich TUM, Tech Univ, Internal Med 2, Klinikum Rechts Isar, Munich, Germany

[14] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA

[15] Merck Co Inc, Oncol Late Dev, Kenilworth, NJ USA

[16] Biometr & Informat Sci, Astrazeneca UK, Cambridge, England

[17] Late Dev Oncol, Oncol R, Astrazeneca US, Gaithersburg, MD USA

[18] GI Canc Drug Dev, Astrazeneca US Time Study, Gaithersburg, MD USA

[19] Univ Chicago, Med Sect Hematol Oncol, Chicago, IL USA

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.796

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1468P

引用

页码：S1086 / S1087

页数：2

共 50 条

[1] POLO: subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer
Arnold, D.
Golan, T.
Hammel, P.
Reni, M.
Van Cutsem, E.
Macarulla, T.
Hall, M. J.
Park, J. O.
Hochhauser, D.
Oh, D. -Y
Reinacher-Schick, A.
Tortora, G.
Alguel, H.
O'Reilly, E. M.
Bordia, S.
McGuinness, D.
Cui, K. Y.
Kindler, H. L.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 221 - 221
[2] POLO: patient-centred outcomes with maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer
Arnold, D.
Yoo, Kyoo H.
Kindler, H. L.
McGuinness, D.
Cui, K. Y.
Joo, S.
Golan, T.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 224 - 224
[3] POLO: Patient-centred outcomes with maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer
Kindler, H.
Yoo, H.
McGuinness, D.
Cui, K.
Joo, S.
Locker, G.
Golan, T.
ANNALS OF ONCOLOGY, 2021, 32 : S134 - S134
[4] POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC)
Van Cutsem, E.
Golan, T.
Hammel, P.
Reni, M.
Macarulla, T.
Hall, M. J.
Park, J. O.
Hochhauser, D.
Arnold, D.
Oh, D-Y.
Reinacher-Schick, A.
Tortora, G.
Alguel, H.
O'Reilly, E. M.
McGuinness, D.
Cui, K. Y.
Schlienger, K.
Locker, G. Y.
Kindler, H. L.
ANNALS OF ONCOLOGY, 2019, 30 : 264 - +
[5] POLO: Patient-Centered Outcomes With Maintenance Olaparib in PatientsWith a Germline BRCA Mutation and Metastatic Pancreatic Cancer
Kindler, H. L.
Yoo, H.
McGuinness, D.
Cui, K. Y.
Joo, S.
Locker, G. Y.
Golan, T.
PANCREAS, 2021, 50 (07) : 1071 - 1071
[6] Extended Overall Survival Results from the POLO Study of active Maintenance Therapy with Olaparib in Patients with metastatic Pancreatic Cancer and a Germline BRCA Mutation
Arnold, D.
Golan, T.
Hammel, P.
Reni, M.
Van Cutsem, E.
Macarulla, T.
Hall, J. M.
Park, Oh J.
Hochhauser, D.
Oh, D. -Y.
Reinacher-Schick, A.
Tortora, G.
Alguel, H.
O'Reilly, M. E.
Kindler, L. H.
Sharan, K.
Ou, X.
Cui, K.
Locker, Y. G.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 224 - 225
[7] Maintenance olaparib in patients aged ≥65 years with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial
Kindler, H.
Hammel, P.
Reni, M.
Van Cutsem, E.
Macarulla, T.
Hall, M.
Park, J.
Hochhauser, D.
Arnold, D.
Oh, D.
Reinacher-Schick, A.
Tortora, G.
Alguel, H.
O'Reilly, E.
McGuinness, D.
Cui, K.
Schlienger, K.
Locker, G.
Golan, T.
ANNALS OF ONCOLOGY, 2020, 31 : S218 - S218
[8] Extended overall survival results from the POLO study of active maintenance olaparib in patients with metastatic pancreatic cancer and a germline BRCA mutation
Arnold, Dirk
Hammel, Pascal
Golan, Talia
Reni, Michele
Van Cutsem, Eric
Macarulla, Teresa
Hall, Michael J.
Park, Joon Oh
Hochhauser, Daniel
Oh, Do-Youn
Reinacher-Schick, Anke
Tortora, Giampaolo
Algul, Hana
O'reilly, Eileen M.
Sharan, Kanu
Ou, Xiaoling
Cui, Karen
Locker, Gershon Y.
Kindler, Hedy L.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 91 - 92
[9] Extended overall survival results from the POLO study of active maintenance olaparib in patients with metastatic pancreatic cancer and a germline BRCA mutation
Hammel, P.
Golan, T.
Reni, M.
Van Cutsem, E.
Macarulla Mercade, T.
Hall, M.
Park, J. O.
Hochhauser, D.
Arnold, D.
Oh, D-Y.
Reinacher-Schick, A.
Tortora, G.
Alguel, H.
O'Reilly, E.
Sharan, K.
Ou, X.
Cui, K. Y.
Locker, G.
Kindler, H.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1137 - S1137
[10] POLO: Long-Term Safety and Tolerability of Olaparib for Patients With a Germline BRCA Mutation and Metastatic Pancreatic Cancer
Kindler, H. L.
Golan, T.
Hammel, P.
Reni, M.
Van Cutsem, E.
Macarulla, T.
Hall, M. J.
Park, J.
Hochhauser, D.
Oh, D.
Reinacher-Schick, A.
Tortora, G.
Alguel, H.
O'Reilly, E. M.
Bordia, S.
McGuinness, D.
Cui, K. Y.
Locker, G. Y.
Arnold, D.
PANCREAS, 2021, 50 (07) : 1071 - 1071

← 1 2 3 4 5 →